413 related articles for article (PubMed ID: 10075504)
1. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients.
Kordossis T; Avlami A; Velegraki A; Stefanou I; Georgakopoulos G; Papalambrou C; Legakis NJ
Med Mycol; 1998 Oct; 36(5):335-9. PubMed ID: 10075504
[TBL] [Abstract][Full Text] [Related]
2. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
3. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
4. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
Saag MS; Graybill RJ; Larsen RA; Pappas PG; Perfect JR; Powderly WG; Sobel JD; Dismukes WE
Clin Infect Dis; 2000 Apr; 30(4):710-8. PubMed ID: 10770733
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
7. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
Soares BM; Santos DA; Kohler LM; da Costa César G; de Carvalho IR; dos Anjos Martins M; Cisalpino PS
Rev Iberoam Micol; 2008 Dec; 25(4):242-5. PubMed ID: 19071894
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
9. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
Wirth F; de Azevedo MI; Pilla C; Aquino VR; Neto GW; Goldani LZ
Med Mycol; 2018 Apr; 56(3):257-262. PubMed ID: 28992308
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cryptococcal meningitis with five anti-fungal drugs: the role of amphotericin B.
Shindo K
Drugs Exp Clin Res; 1990; 16(7):327-32. PubMed ID: 1965500
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
13. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
14. Current approach to the acute management of cryptococcal infections.
Powderly WG
J Infect; 2000 Jul; 41(1):18-22. PubMed ID: 11041709
[No Abstract] [Full Text] [Related]
15. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.
Pedroso RS; Ferreira JC; Candido RC
Mem Inst Oswaldo Cruz; 2006 May; 101(3):239-43. PubMed ID: 16862315
[TBL] [Abstract][Full Text] [Related]
16. [Genotypes and in vitro antifungal susceptibility of Cryptococcus isolates in Sichuan Province].
Lei Y; Xiao YL; He C; Zhang CY; Xie Y; Kang M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jan; 46(1):82-6. PubMed ID: 25807801
[TBL] [Abstract][Full Text] [Related]
17. Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS.
Manfredi R; Fulgaro C; Sabbatani S; Legnani G; Fasulo G
AIDS Patient Care STDS; 2006 Apr; 20(4):227-32. PubMed ID: 16623620
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.
Larsen RA; Leal MA; Chan LS
Ann Intern Med; 1990 Aug; 113(3):183-7. PubMed ID: 2197908
[TBL] [Abstract][Full Text] [Related]
19. [Cryptococcal meningitis].
Biniek R; Hilgenstock F; Schuchardt V
Nervenarzt; 1986 Jan; 57(1):47-55. PubMed ID: 3960220
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS.
Jaruratanasirikul S
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):719-23. PubMed ID: 9253873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
